Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842577 | 0.91 | ACE (0.53) | HTR2CSMN1; SMN2NPC1RAB9AACE | |
| SCHEMBL4799717 | 0.91 | ACE (0.53) | HTR2CSMN1; SMN2NPC1RAB9AACE | |
| SCHEMBL7339038 | 0.91 | ACE (0.53) | HTR2CSMN1; SMN2NPC1RAB9AACE | |
| SCHEMBL4848858 | 0.91 | ACE (0.53) | HTR2CSMN1; SMN2NPC1RAB9AACE | |
| SCHEMBL3843206 | 0.91 | ACE (0.53) | HTR2CSMN1; SMN2NPC1RAB9AACE | |
| SCHEMBL7345709 | 0.89 | SMN1; SMN2 (0.52) | HTR2CSMN1; SMN2NPC1RAB9AACE | |
| SCHEMBL19042 | 0.89 | ACE (0.53) | HTR2CSMN1; SMN2NPC1RAB9AACE | |
| SCHEMBL9877388 | 0.88 | FKBP1A (0.49) | HTR2CSMN1; SMN2NPC1RAB9AACE | |
| SCHEMBL9878033 | 0.88 | FKBP1A (0.49) | HTR2CSMN1; SMN2NPC1RAB9AACE | |
| SCHEMBL4798767 | 0.87 | FKBP1A (0.49) | HTR2CSMN1; SMN2NPC1RAB9AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382261-B2 | Substituted quinazolinones as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-07-05 | — | — | US | disclosed |
| US-9382261-B2 | Substituted quinazolinones as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-07-05 | — | — | US | disclosed |
| US-9126986-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-08 | — | — | US | disclosed |
| US-9126986-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-08 | — | — | US | disclosed |
| US-20140378485-A1 | QUINAZOLINONE DERIVATIVES AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-25 | — | — | US | disclosed |
| US-20140378485-A1 | QUINAZOLINONE DERIVATIVES AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-25 | — | — | US | disclosed |
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | HAVCR2, ZC3HAV1, SUB1 | HTR2C 1888/4885SMN1; SMN2 4847/4885NPC1 225/4885 |
| US-20140378485-A1 | QUINAZOLINONE DERIVATIVES AS HCV INHIBITORS | EIF2AK2, NQO2, IRF3 | HTR2C 2602/4885SMN1; SMN2 4669/4885NPC1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.